Drug intelligence / Profile preview

DS111

Development stage: Preclinical
Lead developer: DS Biopharma
Modality: Small Molecules
Administration: Oral

Overview

DS111 is an investigational oral drug candidate currently in preclinical development by DS Biopharma (formerly Dignity Sciences). The compound is being developed for the treatment of an undisclosed orphan indication. While specific details regarding its molecular target and mechanism of action have not been publicly released, DS Biopharma's research focus generally centers on bioactive lipid-based compounds. As of late 2021, the program remains in the early stages of the company's pipeline, specifically positioned for rare disease applications.

Beyond the preview

Go deeper on DS111.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DS111.

Explore the full profile